Clinical Trial Update: Single-Ascending-Dose Safety/Tolerability of NP001 in Amyotrophic Lateral Sclerosis (ALS) [Phase 1]

View source ↗

Summary

Phase 1 single-ascending-dose study assessing safety and tolerability of NP001 in amyotrophic lateral sclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• NP001

Snippet

Sponsor: Neuraltus Pharmaceuticals, Inc. | Conditions: Amyotrophic Lateral Sclerosis | Phase 1 | Status: COMPLETED